Astronics Corporation is rated a Buy due to a strong order backlog, expanding profit margins, and promising growth prospects for 2027. The company projects 2026 revenue between $1.02 and $1.04 billion, with analysts expecting earnings per share of $3.15 in 2027, supporting a fair value estimate of $79 per share. Its adjusted operating margin has improved significantly from 8.8% in 2024 to 20.3% in Q2 2026, with further margin gains seen as crucial. However, risks include customer concentration with Boeing accounting for 12% of sales, increased competition, challenges in the satellite business, and a pending patent dispute with Lufthansa Technik.
Astronics Corporation is noted here with a focus on its strong profit margin expansion, reaching 20.3% in Q2 2026. For readers following Industrials-sector US stocks, here is Pluang's market snapshot as of Oct 06, 2026 22:52 WIB: out of 93 priced stocks, 71 rose and 21 fell. Notable movers include Comfort Systems USA Inc (FIX) at USD 1,808.00 with a 5.54% increase and a typical hold time of 40 days, GE Vernova Inc (GEV) at USD 1,041.36 up 5.19% with 75% buy order activity and a 36-day hold, and nVent Electric (NVT) at USD 175.63 rising 5.06% with a 10-day hold time.
Stryker experienced an 8.8% stock drop on September 8, 2026, wiping out over $10 billion in market value due to ongoing manufacturing problems that were thought resolved. Truist Financial lowered its price target from $340 to $310, reflecting concern...
Bank OZK is scheduled to release its Q3 2026 earnings after market close on October 20, providing investors with updated financial results to compare against Citigroup's current Sell rating. The bank's latest balance sheet shows $41.70 billion in tot...
Scotiabank has increased its price target for Pfizer stock from $30.00 to $33.00, suggesting a potential upside of 20.9% from the current trading price of $27.31. Pfizer, a major pharmaceutical company, holds a strong buy rating with a Zacks Rank of ...
Citigroup has raised its price target for AstraZeneca to £186.00 from £178.00, maintaining a Buy rating following successful Phase 3 clinical trials. The increase reflects higher peak sales forecasts for drugs tozorakimab and SERENA-6, offsetting the...
An analyst from BMO Capital set a $67 price target for Devon Energy, suggesting a 40% upside from its current share price of around $48. The oil and gas producer has consistently beaten earnings estimates recently, showing strong financial health. Ho...
